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Reply
We thank Dr. Ezekowitz and Dr. Westenbrink et al. for their
interest in our recent study (1). In general, their letters raise issues
and questions that only further research can answer. Our study
design did not allow the drawing of conclusions regarding the
prevalence of anemia, and the only apparent explanation for the
under-representation of women (2 of 37 patients) is that far fewer
women than men are admitted to our hospital. Our study focused
on patients with “clinically significant” anemia (hemoglobin con-
tent 12 g/dl in men and 11.5 g/dl in women) who not only
needed to be treated, but also had to undergo extensive diagnostic
tests, including bone marrow aspiration.
A ferritin concentration 30 ng/ml, used instead of 17 ng/ml
as an indication of depleted iron stores, is associated with a higher
positive predictive value for iron-deficiency anemia (2). However,
using this higher ferritin concentration increased the number
(proportion) of patients from 2 (7.4%) to only 5 of 27 (18.5%)
patients. Thus, ferritin remains an unreliable marker of iron
deficiency in patients suffering from heart failure. Unfortunately,
we did not measure their saturation index.
We agree that our study does not provide insights into the
mechanism(s) of iron deficiency. However, in our discussion we do
emphasize that “iron deficiency anemia in these desperately ill
patients. . . seems to be multifactorial and at least partially the
result of a defective release of iron from cells,” although we do not
have the data to support this hypothesis.
Although it is, indeed, likely that some iron accumulates in
storage sites of the reticulo-endothelial system in these patients,
this accumulation would not be limited to the liver and spleen, and
would include macrophages in the bone marrow. Smears of the
latter are stained for iron with standard Prussian blue and are
counterstained with safranin. With this stain, the hemosiderin
granules appear as blue/green and the cells are purple/red. In
iron-deficiency anemia, by definition, hemosiderin granules are not
detected by photomicroscopy either in the macrophages of the
bone marrow or in the erythroblasts (3). Such was the case in 25
patients whose iron stores were depleted (grade 0) out of 27
patients included in our study. In addition, patients presenting
with chronic heart failure respond to intravenous iron replacement
(4) supporting the hypothesis of a central role played by iron
deficiency in this clinical setting.
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